We take mature digital health startups and enhance them with our expertise in innovation, global entrepreneurship, and investment strategy.
From our eclectic team, to our long and successful investment history, to our multinational presence, Infinity Medical is the right company to bring the following portfolio startups to their optimal market positioning.
Genoox’s advanced AI for management and analysis of genetic information allows comprehensive, personalized medical diagnoses.
Genoox’s “Franklin” is the first cooperative global platform for gathering genetic data, accumulated through thousands of examinations, in a single and widely accessible database. This database leverages information provided by global user communities composed of hundreds of corporations, medical organizations, and patients. Through a cloud-based network, Genoox allows patient staff to access and analyze this information, compare it to global data, form new insights, and deliver extensive clinical diagnoses.
The goal of Genoox is to accelerate diagnostic processes by improving precision and ease of testing based on the specific genetic structure of each patient. The primary users of the Genoox solution are hospitals, healthtech and pharmaceutical companies, and development centers.
According to Genoox, they have the largest combined genetic and symptom database in the world in terms of size and quality. Moreover, the database is constantly updated because of the constant input from a global community of genetic experts. At present, the Genoox database holds genetic information related to 65,000 cases, 800 M variants, 700 connected organizations, and 250,000 user indications. The database has been searched 25 M times.
Biobeat’s unique technology is based on a PPG sensor that has a registered global patent. The sensor enables a clear and accurate reading of the PPG signal wave and allows the measurement of various vital signs. The company also has numerous other devices with registered and pending patents at various stages.
Biobeat began sales in 2019. The company’s main clients are some of the world’s largest pharmaceutical companies and numerous major hospital groups in the US, as well as Israeli hospitals. Today, 75% of the company’s revenues are from the US and 25% from Europe. 35% of these revenues are from various pharmaceutical companies and the remainder from hospitals and chronic care facilities.
In 2021, the company expects a rapid expansion of demand.
Biobeat Medical Smartmonitoring provides wireless patient monitoring solutions for both clinical and at-home use.
Biobeat has two products with FDA approval – a remote medical monitoring watch for home use, and a disposable chest monitor for hospital use. Both devices are backed up by proprietary monitoring systems:
▪ The Early Warning Score system is based on the NEWS protocol, and provides real time warnings of deteriorating patient vital signs along with customizable alert thresholds.
▪ The company’s web monitoring management platform is a cloud-based system for department-wide management. It provides a patient’s medical history in various formats and a reporting function that includes highly scalable granularity.
Polaris Quantum Biotech, based in Durham, NC, develops a system for the computerized design of drugs using quantum computers. Matching the speed of
Quantum Computers, their technology accelerates the drug development processes by over 10 times.
Quantum Computing technology has reached an inflection point and embodies an unprecedented potential for accelerating the power of computing, and the use of new computing capabilities. The company, founded by Dr. Shahar Keinan, CEO, and Bill Shipman, CTO, uses unique algorithms and advanced quantum computing. The Polaris platform operates on both cloud and quantum computers and enables the optimization of molecular drugs by accelerated computing software while maintaining maximum accuracy. The platform incorporates the ability to store information and arrange it in a way that allows the analysis of artificial intelligence.
Polaris will design the drugs on the computer, synthesize and perform the initial activity and properties tests, then execute the patent on the drug. At this point, the drug will be licensed (or entered into a collaboration agreement) to a pharmaceutical or biotechnology company. The company’s customers are divided into two types: pharmaceutical companies that license drugs that the company develops and companies that buy drug design services from the company.
POLARISqb is transforming health for people everywhere, by the fast creation of drug blueprints for all human proteins, disease pathways, genetic mutations and pathogens.
POLARISq’s goal is to unite the powers of Quantum Computing, AI and Precision Medicine to search chemical space and create novel molecular drugs for specific proteins and diseases.
Cynerio is focused on ensuring patient safety and data protection by securing the connected medical device ecosystem. The company’s custom solutions for healthcare providers combine behavior learning with medical workflow analysis to provide full visibility into medical device behavior and activity on the network, detect anomalies, and stop threats in order to ensure patient safety and data protection.
The Cynerio Healthcare IoT platform provides healthcare facilities with a comprehensive suite of solutions that caters to every IT need, from healthcare-safe Zero Trust cybersecurity to asset and risk management. Cynerio’s platform covers every connected asset, whether it’s medical/IoMT, Enterprise IoT, or an OT system – and every threat vector, equipping hospitals with the tools, insight, and control they need to get cyber-secure fast and stay secure.
Cynerio’s mission is to empower healthcare facilities with the control, foresight, and adaptability they need to stay compliant and proactively manage every connection on their own terms.
They equip hospitals with the means to accomplish real security while continuing to ensure patient safety, data confidentiality, and service continuity. Their all-inclusive, healthcare-specific suite of solutions is flexible and scalable, providing hospitals with the threat mitigation tools they need to proactively prevent breaches, reduce the attack surface, and bolster their organization-wide security posture.
Cynerio was named a cool vendor in “Cool Vendors in Cyber-Physical Systems Security, 2020” by the Gartner Research Group
Theranica’s Nerivio Migra is a migraine-relief patch that provides migraine treatment through neuromodulation. Instead of placing electrodes on their head, patients can attach Theranica’s clinically tested, wearable patch to their arm and launch a personalized pain-relief program.
Theranica is the developer of Nerivio, a fully integrated, self-contained family of therapeutic patches. The patches and other types of wearables in the company’s pipeline are controlled by smartphone applications to easily adapt therapy treatments to everyday life.
Theranica combines electrical neurostimulation and neuromuscular stimulation technologies with modern wireless communication and smartphone applications. The company uses these advanced technologies to design and deliver effective products for treating a variety of severe and common medical problems.
In May 2019, Theranica won FDA De Novo clearance for its Nerivio Migra device. In June 2019, the company announced the establishment of a wholly owned subsidiary company, Theranica USA, headquartered in Montclair, New Jersey.
Nerivio appeared on TIME’s List of 100 Best Inventions of 2019. Theranica was also listed as one of 36 game-changing companies in 2020 by New York-based research firm CB Insights.
CytoReason’s unique technology provides a computer system that performs modeling of the human body using existing information from the world of Biology. The mapping allows the evaluation of the function and activity of the proteins in each type of cell, so that the success and portrait of drugs and experiments can be predicted. CytoReason’s technology is based on a huge library of humane molecular information and includes an artificial intelligence platform that allows the world’s leading drug companies to optimize the most appropriate drug for the patient, and even predict how patients will respond to a particular drug.
The company, founded by David Harel, CEO of CytoReason, and based on research by Prof. Shai Shen-Or from the Technion (who serves as the company’s chief scientist), is currently working with 6 of the 10 largest pharmaceutical companies in the world, with emphasis on diseases involving the immune system. The innovative model they have developed allows in addition to promoting new drugs or converting existing drugs to various diseases, to save a lot of money for pharma companies, and significantly shorten development time.